



PEI Pharmacare
P.O. Box 2000
Charlottetown, PE
C1A 7N8
www.princeedwardisland.ca



Programmes provinciaux de médicaments
C.P. 2000
Charlottetown, PE
C1A 7N8
www.princeedwardisland.ca

PEI Pharmacare Bulletin

Issue (2025-18)

August 26, 2025

NEW PRODUCT(S) ADDED TO THE PEI PHARMACARE FORMULARY **(EFFECTIVE DATE: SEPTEMBER 9, 2025)**

Product (Generic name)	Product (Brand name)	Strength	Dosage Form	DIN	MFR
Nicotine	Nic-Hit Liquid Nicotine	1 mg 2 mg	Liquid Spray	80054636 80060452	NHI
Criteria	Open benefit				
Program Eligibility	Smoking Cessation Program				

PEI BIOSIMILAR INITIATIVE REMINDERS

Effective September 1st, originator products Stelara® and Prolia® will be delisted from the PEI Pharmacare Formulary.

Ustekinumab (Stelara®)

- Patients with existing PEI Pharmacare coverage for Stelara® will need to switch to a biosimilar version before **August 31, 2025**, or by the renewal date of their current special authorization, whichever is earlier, to maintain coverage through PEI Pharmacare. A reminder that once a patient is switched to an ustekinumab biosimilar the annual reassessment of the patient and submission of a new Special Authorization Request Form is no longer required. (For patients newly starting on ustekinumab, the submission of an initial request and subsequent renewal will still be required; however, coverage will be set up long term thereafter assuming confirmation of continued response to therapy).

Denosumab (Prolia®)

- Patients with existing PEI Pharmacare coverage for Prolia® will need to switch to the biosimilar version before **August 31, 2025**, to maintain coverage through PEI Pharmacare. A new special authorization request for the biosimilar is not required.

A reminder that pharmacists may be reimbursed for a therapeutic substitution as outlined in the Professional Services Reimbursement Framework on the Resources for Community Pharmacies webpage at <https://src.healthpei.ca/resources-community-pharmacies>.